| Literature DB >> 32781172 |
Julius Krause1, Christoph Rosenbaum1, Michael Grimm1, Adrian Rump1, Rebecca Keßler2, Norbert Hosten2, Werner Weitschies3.
Abstract
For the therapy of esophageal diseases such as eosinophilic esophagitis, there are no possibilities of local targeted therapy. This publication describes a novel, innovative drug delivery concept, that enables a targeted, long-lasting administration of drug substances to the esophageal mucosa. In addition to a comprehensive in-vitro characterization of the dosage form, this work includes a proof-of-concept study with healthy volunteers, which shows the functionality and acceptance of this novel drug delivery concept. This novel drug delivery technology enables for the first time a targeted, local and long-lasting therapy of the esophagus.Entities:
Keywords: Drug delivery; Eosinophilic esophagitis; Esophageal diseases; Esophagus therapy; MRI study
Mesh:
Year: 2020 PMID: 32781172 DOI: 10.1016/j.jconrel.2020.08.011
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776